The Sachs-Bloomberg Annual Global Biotech Forum for Investing & Partnering is a highly transactional international meeting which draws together an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. The event annually attracts an audience of over 400 industry players.

The programme looks jointly at issues regarding biopartnering and bioinvesting, with a series of in-depth panel discussions led by international executives from leading investors, pharmas and biotechs.

WEDNESDAY 31ST MARCH 2004
Pre-Conference Workshop
Biotechnology: from the Benchtop to the Boardroom
The Key Steps for Early Stage Commercialization
For a full overview of this Workshop <click here>

THURSDAY 1ST APRIL 2004
Opening Panel: Venture Financing Outlook for Biotech in 2004
  • Michael Lytton, General Partner, Oxford Bioscience Partners
  • Jean M. George, General Partner, Advance Technology Ventures
  • Dr. Christoph Westphal, General Partner, Polaris Venture Partners
  • James M. Garvey, CEO & Managing Partner, Schroder Ventures Life Sciences
    • Plenary Presentation
  • Stelios Papadopoulos, Ph.D, Vice Chairman, SG Cowen Securities Corporation
    • Panel: Capital Markets
  • Michael King, Managing Director, Healthcare Group, Banc of America
  • R. Nelson Campbell, Senior Vice President, Life Sciences Investment Banking,
    • Friedman, Billings, Ramsey
  • Dr. Sam Fazeli, Senior Biotechnology Analyst, Nomura
    • Panel: Evolving Pharma/Biotech Relationships
  • Eileen Smith Ewing, Esq., Partner & Chair, Life Sciences Group, Kirkpatrick & Lockhart LLP
  • Dr. Maggie Flanagan, Global Alliance Director, Enabling Science, Technology and Information, AstraZeneca Pharmaceuticals
  • Jan van Heek, Executive Vice President, Therapeutics & Genetics, Genzyme Corporation
  • Dr. Jeremy Levin, Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research
  • Dr. Ravi Kiron, Global Head, Strategic Analysis & Knowledge Management Strategic Alliances Global Research & Development, Pfizer Global R&D
    • Panel: Fund of Funds
  • William C. Mills III, Partner, Advent International
  • Matthew I. Hermann, Director, Strategic Health Venture Investing, Ascension Health Ventures
  • Gregory V. Stento, Managing Director, HarbourVest Partners, LLC
  • Robert E. Mast, Managing Director, Monument Group
  • Otello Stampacchia, Ph.D., Head of Life Sciences Investments, NIB Capital Private Equity
    • Panel: Global Development
  • N. Peter Kostopulos, Leader BioAlliance Practice & Partner Life Sciences, Womble Carlyle
  • Pierre Cantin, Partner, Biotechnology & Life Sciences, CDP Capital – Technology Ventures
  • Mark R. Saunders, President, Global Markets Capital Group, LLC
  • Antoine Papiernik, General Partner, Sofinnova Partners
    • FRIDAY 2ND APRIL 2004
    Plenary Presentation: Technology Transfer
  • Theodore J. Roumel, Office of Technology Transfer, National Institutes of Health
    • Panel Discussion: Technology Transfer Panel
    Successfully Transferring Technology into the Marketplace
  • Lita Nelsen, Director, Technology Licensing Office, Massachusetts Institute of Technology
  • O. Prem Das, Ph.D., Director, Office of Technology Licensing & Industry Sponsored Research, Harvard Medical School
  • Dr. John Burt, Head of Medical Sciences Team, Imperial College Innovations
  • Jean-Pierre Saintouil, Director, Office of Technology Transfer, INSTITUT PASTEUR - Paris, France
    • Keynote Panel: Value Creation in Biotechnology
  • Hoda Abou-Jarma, Founder & CEO, BioExec Ventures LLC
  • Jean-François Formela, Senior Partner, Atlas Venture
  • Ansbert Gadicke, MD, Founding General Partner & Chairman, MPM Capital
  • Noubar B. Afeyan, Ph.D., Senior Managing Director & CEO, Flagship Ventures
  • Jean-Pierre Sommadossi Ph.D., Founder, CEO & Chairman, Idenix Pharmaceuticals
  • Steven Holtzman, CEO, Infinity Pharmaceuticals
  • Dr. Edward M. Scolnick, President Emeritus, Merck Research Laboratories
    • Panel: Clinical Trials & Drug Development
    Assessing the Cost of Clinical Trials & Identifying The Key Issues in Drug Development
  • Richard E. Kuntz, M.D., M.Sc, Chief Scientific Officer, Harvard Clinical Research Institute, Chief, Division of Clinical Biometrics, Brigham & Women’s Hospital, Associate Professor Medicine, Harvard Medical School
    • Panel: Systems Biology
    Is This The Right Time To Invest?
  • Dr. James Fickett, Director, Strategic Capabilities, Discovery IS and Informatics, AstraZeneca Pharmaceuticals
  • Steve Ober, President, Beyond Genomics
  • Dr. Robert Mashal, Partner, Boston Millennia Partners
  • Robert Mulroy, President & CEO, Merrimack Pharamceuticals
    • Panel: Emerging Markets
    Examining The Growth of Biotech Industries in Asia-Pacific, Australia, China and India
  • Stan Yakatan, Chairman, Katan Associates
  • Dr. Vibha Ahuja, Deputy General Manager, Biotech Consortium India Limited
  • Dr. Gurinder Shahi, CEO, BioEnterprise Asia
  • Mario Gobbo, Head of Life Sciences, International Finance Corporation
  • Dr. Nathan Zhang, President, China ChipScreen Biosciences

    • Sector Workshops:
    In addition, the programme features more than 45 company presentations from a range of publicly listed and private life science companies, looking to raise finance and/or partners. With specialist workshops on:

    » Small-Cap & Pre-IPO
    » Immunology/Oncology
    » Therapeutics
    » Post-Genomics: Pharmacogenomics & Proteomics
    » Bioinformatics, SNP, Array Technology
    » Medical Devices, Diagnostics

     
    back to top